Dermata Therapeutics- Warrants (13/08/2026) Common Stock

Dermata Therapeutics- Warrants (13/08/2026) (DRMAW) currently reports a common stock of $400 as of June 2026. That compares with $64 in the prior-year period — up 528.1% year over year. Use the charts on this page to explore Dermata Therapeutics- Warrants (13/08/2026)'s common stock history and peer comparisons.

Dermata Therapeutics- Warrants (13/08/2026)'s common stock increased from $64 to $400 — a 528.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dermata Therapeutics- Warrants (13/08/2026) reported $400 in common stock as of June 2026. That compares with $64 in the prior-year period — up 528.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $400, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dermata Therapeutics- Warrants (13/08/2026), and consider following DRMAW for alerts when major investors trade the stock.

Dermata Therapeutics- Warrants (13/08/2026) is classified in the Healthcare sector. On common stock, it currently shows $400. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRMAW with unrelated industries.